Original articles

Report of a case of activated phosphoinositide 3-kinase δ syndrome with onset of repeated bloody stool and review of literature

Expand
  • 1a. Department of Pediatrics, 1b. Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Department of Pediatrics, Ruijin North Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201821, China

Received date: 2019-04-01

  Online published: 2019-06-25

Abstract

Objective: To investigate the clinical features, endoscopic appearance and genetic characteristic of a child with activated phosphoinositide 3-kinase δ syndrome (APDS) with onset of recurrent bloody stools. Methods: A 19-month-old girl who was diagnosed with APDS because of PIK3CD mutation was admitted into Ruijin Hospital in December 2018. The clinical manifestations, biochemical tests, immunological function, treatment, and follow-up of the patient were analyzed.And Chinese database and PUBMED database were searched for literature review. Results: The child had chronic diarrhea and suffered intestinal infection for 4 times. Serum immunoglobulin levels were decreased: IgG 1.16 g/L,IgA 0.11 g/L, IgM 2.81 g/L. The T cell subset detection found increased CD8+ and decreased CD4+: CD3+ 61.30%, CD3+CD4+ 26.30%, CD3+CD8+ 33.80%, CD56+CD16+ 27.80%, CD19+10.40%. Colonoscopy found lymphonodular hyperplasia. A mutation of c.3061G>A(p.E1021K) in PIK3CD gene was found by whole-exome sequencing. Related literature searched showed that APDS patients had repeated respiratory infections, CM virus and/or EB virus infection, lymphoid tissue hyperplasia as the main manifestations. Conclusions: This is the first report of a case of APDS with onset of recurrent bloody stool in our country. For low aged children who has repeated bloody stools, especially those with lymphonodular hyperplasia found under colonoscopy, should have abnormal immunological findings tested and differentiated from primary immunodeficiency diseases.APDS could be diagnosed by relevant genetic test.

Cite this article

YANG Yuanyan, XIAO Yuan, CHEN Xiaoyan, SU Wen, XU Chundi, ZHANG Qingqing . Report of a case of activated phosphoinositide 3-kinase δ syndrome with onset of repeated bloody stool and review of literature[J]. Journal of Diagnostics Concepts & Practice, 2019 , 18(03) : 296 -300 . DOI: 10.16150/j.1671-2870.2019.03.010

References

[1] Angulo I, Vadas O, Garçon F, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage[J]. Science, 2013, 342(6160):866-871.
[2] 唐文静, 王薇, 罗颖, 等. PIK3CD基因突变致PI3Kδ过度活化综合征临床及免疫学特点分析[J]. 中华儿科杂志, 2017, 55(1):19-24.
[3] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[4] Teranishi H, Ishimura M, Koga Y, et al. Activated phosphoinositide 3-kinase δ syndrome presenting with gut-associated T-cell lymphoproliferative disease[J]. Rinsho Ketsueki, 2017, 58(1):20-25.
[5] Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study[J]. J Allergy Clin Immunol, 2017, 139(2):597-606.
[6] Sullivan KE, Conrad M, Kelsen JR. Very early-onset inflammatory bowel disease: an integrated approach[J]. Curr Opin Allergy Clin Immunol, 2018, 18(6):459-469.
[7] Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study[J]. J Allergy Clin Immunol, 2016, 138(1):210-218.
[8] Dulau Florea AE, Braylan RC, Schafernak KT, et al. Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD[J]. J Allergy Clin Immunol, 2017, 139(3):1032-1035.
[9] Sinclair LV, Finlay D, Feijoo C, et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking[J]. Nat Immunol, 2008, 9(5):513-521.
[10] Dornan GL, Siempelkamp BD, Jenkins ML, et al. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1[J]. Proc Natl Acad Sci U S A, 2017, 114(8):1982-1987.
[11] Burke JE, Vadas O, Berndt A, et al. Dynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110α[J]. Structure, 2011, 19(8):1127-1137.
[12] Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency[J]. Nat Immunol, 2014, 15(1):88-97.
Outlines

/